← United Therapeutics overview

United Therapeutics vs Vertex Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

United Therapeutics Corporation (UTHR)

Q3 2026
▲4▼3

Legal Win and Organ Flights Boost UTHR, but Competition and Analyst Caution Linger

  • Court Blocks Liquidia's Yutrepia in PH-ILD A Delaware court blocked Liquidia's Yutrepia in PH-ILD, a key lung disease. This protects UTHR's Tyvaso franchise and sent shares up 12.5%.

    This legal win directly removes a competitive threat and caused a sharp stock jump.

  • Manufactured Organs Flown on eVTOL United Therapeutics advanced its organ-delivery story by flying manufactured organs on the first U.S. eVTOL pilot flights, moving closer to its long-term goal of providing transplantable organs.

    This milestone supports the company's long-term growth narrative and differentiates it from peers.

  • Phase 3 Data Supports Two FDA Filings New Phase 3 data supported two FDA filings, potentially expanding UTHR's product labels and driving future revenue growth.

    Positive clinical data and regulatory filings are key catalysts for future sales.

  • Accelerated Buyback Returns $477.6 Million UTHR returned $477.6 million to shareholders via an accelerated buyback, signaling confidence and supporting the stock price.

    Buybacks reduce share count and often boost investor sentiment.

  • Liquidia's Yutrepia Gains PAH Share Liquidia's Yutrepia continues to gain share in PAH, threatening UTHR's Tyvaso franchise. This competitive pressure weighs on the stock.

    Ongoing competitive threat to core revenue stream.

  • Judge Criticizes Deceptive Patent Document A judge criticized UTHR for a deceptive, backdated patent-fight document, raising legal and reputational concerns.

    This legal issue could lead to penalties and damage trust.

  • Goldman Sachs Initiates with Sell Rating Goldman Sachs initiated coverage with a Sell rating, doubting UTHR's 2029 targets. This analyst caution adds pressure on the stock.

    Analyst downgrade can influence investor sentiment and stock performance.

  • New Tresmi Inhaler Could Defend Tyvaso The new Tresmi inhaler could help defend the Tyvaso franchise against competition, but its impact is uncertain and competition remains intense.

    Potential positive product but not yet proven, so mixed effect.

September 2026
▲3▼1

UTHR wins key patent ruling, but competition and analyst caution weigh

  • Court ruling blocks rival Yutrepia in PH-ILD A Delaware court ruled that Liquidia's Yutrepia infringes United Therapeutics' patent on inhaled treprostinil for PH-ILD. This could restrict Yutrepia's use in that lung condition, reducing competition for UTHR's Tyvaso and Tyvaso DPI, and UTHR may also win money damages. The stock jumped 12.5% on the news.

    This is the biggest new event, directly lifting UTHR by weakening a rival and protecting its top-selling franchise.

  • New data supports two FDA filings United Therapeutics presented new analyses from its Phase 3 trials of ralinepag and inhaled treprostinil for IPF at European medical meetings. The data showed clinical benefits, supporting two FDA applications filed in June. If approved, these could expand UTHR's treatable patient groups and add billions in revenue.

    This is a fresh positive catalyst that strengthens the case for two potential new products.

  • Company returns $477.6 million to shareholders United Therapeutics committed the last $477.6 million of its $2 billion buyback to an accelerated share repurchase. This brings total capital returned to about $4 billion in two and a half years. Buybacks reduce the number of shares, which can lift earnings per share and support the stock price.

    This is a new capital-return action that directly affects share count and investor sentiment.

  • Goldman Sachs starts coverage with Sell rating Goldman Sachs initiated coverage of United Therapeutics with a Sell rating, questioning whether the company can hit its 2029 revenue and earnings targets. The analyst doubts the ambitious pipeline can deliver as expected. This adds a fresh negative voice and could pressure the stock until upcoming FDA decisions provide clarity.

    This is a new analyst action that introduces a notable counterweight to the positive patent news.

Latest
▲3▼1

UTHR wins key patent ruling, but competition and analyst caution weigh

  • Court ruling blocks rival Yutrepia in PH-ILD A Delaware court ruled that Liquidia's Yutrepia infringes United Therapeutics' patent on inhaled treprostinil for PH-ILD. This could restrict Yutrepia's use in that lung condition, reducing competition for UTHR's Tyvaso and Tyvaso DPI, and UTHR may also win money damages. The stock jumped 12.5% on the news.

    This is the biggest new event, directly lifting UTHR by weakening a rival and protecting its top-selling franchise.

  • New data supports two FDA filings United Therapeutics presented new analyses from its Phase 3 trials of ralinepag and inhaled treprostinil for IPF at European medical meetings. The data showed clinical benefits, supporting two FDA applications filed in June. If approved, these could expand UTHR's treatable patient groups and add billions in revenue.

    This is a fresh positive catalyst that strengthens the case for two potential new products.

  • Company returns $477.6 million to shareholders United Therapeutics committed the last $477.6 million of its $2 billion buyback to an accelerated share repurchase. This brings total capital returned to about $4 billion in two and a half years. Buybacks reduce the number of shares, which can lift earnings per share and support the stock price.

    This is a new capital-return action that directly affects share count and investor sentiment.

  • Goldman Sachs starts coverage with Sell rating Goldman Sachs initiated coverage of United Therapeutics with a Sell rating, questioning whether the company can hit its 2029 revenue and earnings targets. The analyst doubts the ambitious pipeline can deliver as expected. This adds a fresh negative voice and could pressure the stock until upcoming FDA decisions provide clarity.

    This is a new analyst action that introduces a notable counterweight to the positive patent news.

July 2026
▲2▼2

UTHR's organ-delivery flights advance, but PAH competition and patent setback weigh

  • Manufactured organs flown on first eVTOL pilot flights United Therapeutics' manufactured organs were carried on the first US eVTOL integration pilot flights between Virginia and Maryland. This shows a real use for its organ products and could open a new delivery route, supporting the long-term growth story that helps lift the stock.

    New concrete validation of UTHR's organ business and logistics use case.

  • Liquidia's Yutrepia keeps taking PAH market share Liquidia's competing PAH drug Yutrepia posted about $130 million in first-quarter sales, with thousands of patients starting it. It is winning new patients and expanding into more lung conditions, which threatens United Therapeutics' core Tyvaso franchise and caps the stock's upside.

    Shows the competitive threat to UTHR's main revenue source is growing.

  • Judge criticizes United Therapeutics in patent fight A judge said United Therapeutics gave a deceptive and backdated answer in its patent dispute with Liquidia, and asked who changed the document. The stock slipped on the news. A bad ruling could weaken UTHR's legal position against a rival, so investors see added risk.

    New legal setback that could affect UTHR's ability to defend its PAH patents.

  • New Tresmi inhaler could defend the Tyvaso franchise United Therapeutics unveiled Tresmi, a soft-mist inhaler its CEO called a category killer. It could replace lost Tyvaso DPI royalties and help hold off rivals like Yutrepia. A strong new product supports future sales, which is good for the stock.

    New product that may offset competitive and royalty pressures on UTHR's PAH business.

▲2▼2

UTHR's organ-delivery flights advance, but PAH competition and patent setback weigh

  • Manufactured organs flown on first eVTOL pilot flights United Therapeutics' manufactured organs were carried on the first US eVTOL integration pilot flights between Virginia and Maryland. This shows a real use for its organ products and could open a new delivery route, supporting the long-term growth story that helps lift the stock.

    New concrete validation of UTHR's organ business and logistics use case.

  • Liquidia's Yutrepia keeps taking PAH market share Liquidia's competing PAH drug Yutrepia posted about $130 million in first-quarter sales, with thousands of patients starting it. It is winning new patients and expanding into more lung conditions, which threatens United Therapeutics' core Tyvaso franchise and caps the stock's upside.

    Shows the competitive threat to UTHR's main revenue source is growing.

  • Judge criticizes United Therapeutics in patent fight A judge said United Therapeutics gave a deceptive and backdated answer in its patent dispute with Liquidia, and asked who changed the document. The stock slipped on the news. A bad ruling could weaken UTHR's legal position against a rival, so investors see added risk.

    New legal setback that could affect UTHR's ability to defend its PAH patents.

  • New Tresmi inhaler could defend the Tyvaso franchise United Therapeutics unveiled Tresmi, a soft-mist inhaler its CEO called a category killer. It could replace lost Tyvaso DPI royalties and help hold off rivals like Yutrepia. A strong new product supports future sales, which is good for the stock.

    New product that may offset competitive and royalty pressures on UTHR's PAH business.

Q2 2026
▲2▼2

Pipeline Wins and New Deals Offset Weak Sales and Rising Competition

  • FDA Approves LungFX Device United Therapeutics won FDA approval for its LungFX device, which helps assess donor lungs that would otherwise be discarded. This opens a new revenue stream in organ transplantation and supports the company's long-term growth story, pushing the stock up.

    This is a new regulatory win that expands the company's business and is a fresh positive catalyst.

  • Acquires Thymmune for $140 Million United Therapeutics bought Thymmune Therapeutics for $140 million cash, adding a regenerative thymic cell therapy platform. This expands its pipeline in organ transplantation and immune therapies, signaling long-term growth and boosting investor confidence.

    A new acquisition that adds technology and pipeline depth, directly affecting future growth prospects.

  • Q1 Revenue Miss and Decline United Therapeutics reported Q1 revenue of $781.5 million, down 1.6% from a year ago and missing estimates. This weak financial performance, especially compared to peers, weighs on the stock as investors worry about near-term sales trends.

    A new earnings report showing a revenue miss and decline, which directly pressures the stock price.

  • Liquidia's YUTREPIA Gains Ground Liquidia's competing PAH drug YUTREPIA is growing fast, with annualized revenue near $520 million and most new patients treatment-naive. This competition threatens United Therapeutics' core PAH franchise, especially as its nebulized Tyvaso sales decline, capping upside.

    A new update on a direct competitor's rapid growth, which increases competitive pressure on UTHR's key products.

June 2026
▲2▼2

Pipeline Wins and New Deals Offset Weak Sales and Rising Competition

  • FDA Approves LungFX Device United Therapeutics won FDA approval for its LungFX device, which helps assess donor lungs that would otherwise be discarded. This opens a new revenue stream in organ transplantation and supports the company's long-term growth story, pushing the stock up.

    This is a new regulatory win that expands the company's business and is a fresh positive catalyst.

  • Acquires Thymmune for $140 Million United Therapeutics bought Thymmune Therapeutics for $140 million cash, adding a regenerative thymic cell therapy platform. This expands its pipeline in organ transplantation and immune therapies, signaling long-term growth and boosting investor confidence.

    A new acquisition that adds technology and pipeline depth, directly affecting future growth prospects.

  • Q1 Revenue Miss and Decline United Therapeutics reported Q1 revenue of $781.5 million, down 1.6% from a year ago and missing estimates. This weak financial performance, especially compared to peers, weighs on the stock as investors worry about near-term sales trends.

    A new earnings report showing a revenue miss and decline, which directly pressures the stock price.

  • Liquidia's YUTREPIA Gains Ground Liquidia's competing PAH drug YUTREPIA is growing fast, with annualized revenue near $520 million and most new patients treatment-naive. This competition threatens United Therapeutics' core PAH franchise, especially as its nebulized Tyvaso sales decline, capping upside.

    A new update on a direct competitor's rapid growth, which increases competitive pressure on UTHR's key products.

▲2▼2

Pipeline Wins and New Deals Offset Weak Sales and Rising Competition

  • FDA Approves LungFX Device United Therapeutics won FDA approval for its LungFX device, which helps assess donor lungs that would otherwise be discarded. This opens a new revenue stream in organ transplantation and supports the company's long-term growth story, pushing the stock up.

    This is a new regulatory win that expands the company's business and is a fresh positive catalyst.

  • Acquires Thymmune for $140 Million United Therapeutics bought Thymmune Therapeutics for $140 million cash, adding a regenerative thymic cell therapy platform. This expands its pipeline in organ transplantation and immune therapies, signaling long-term growth and boosting investor confidence.

    A new acquisition that adds technology and pipeline depth, directly affecting future growth prospects.

  • Q1 Revenue Miss and Decline United Therapeutics reported Q1 revenue of $781.5 million, down 1.6% from a year ago and missing estimates. This weak financial performance, especially compared to peers, weighs on the stock as investors worry about near-term sales trends.

    A new earnings report showing a revenue miss and decline, which directly pressures the stock price.

  • Liquidia's YUTREPIA Gains Ground Liquidia's competing PAH drug YUTREPIA is growing fast, with annualized revenue near $520 million and most new patients treatment-naive. This competition threatens United Therapeutics' core PAH franchise, especially as its nebulized Tyvaso sales decline, capping upside.

    A new update on a direct competitor's rapid growth, which increases competitive pressure on UTHR's key products.

Vertex Pharmaceuticals Inc (VRTX)

Q3 2026
▲3▼1

Vertex beats Q2, buys Crinetics, but faces competition and premium valuation

  • Strong Q2 results and buyback Vertex reported Q2 revenue up 12% to $3.3 billion, raised full-year guidance, and announced a $1.42 billion share buyback. This shows the core business is performing well and returning cash to shareholders.

    This is new financial information that directly reflects the company's current performance and capital return.

  • Crinetics acquisition adds diversification Vertex completed the $10 billion acquisition of Crinetics Pharmaceuticals, adding up to $5 billion in peak annual sales and diversifying beyond cystic fibrosis. The deal is expected to boost revenue immediately and contribute to operating profit by 2029.

    This is a major strategic move that expands Vertex's product portfolio and long-term growth prospects.

  • Pipeline and regulatory wins Casgevy's pediatric expansion, positive inaxaplin kidney data, and a rival CF drug failure strengthen Vertex's outlook. Morgan Stanley initiated coverage with an Overweight rating and a $665 price target.

    These events improve the company's competitive position and future revenue potential.

  • Competition and valuation risks Novartis' Fabhalta is already approved in IgA nephropathy, threatening Vertex's povetacicept (FDA decision due Nov 30, 2026). The Crinetics deal carried a roughly 100% premium, and Vertex trades at a premium valuation with slipping 2026 earnings estimates.

    These are real counterweights that could pressure the stock if execution falters.

August 2026
▲3▼1

Vertex gains on rival CF failure, buyback, and pipeline wins

  • Rival CF drug failure removes competitive threat Sionna's CF drug failure eliminated a potential competitor, strengthening Vertex's dominant position in cystic fibrosis and boosting investor confidence.

    This is a new competitive development that directly benefits Vertex's core franchise.

  • Q2 beat, raised guidance, and $1.42B buyback Vertex reported Q2 revenue of $3.33B (up 12.5%), raised 2026 guidance to $13.1–13.2B, and announced a $1.42B buyback, signaling strong financial health.

    These are new financial updates that directly support the stock price.

  • Non-CF drugs gain traction; pipeline advances Journavx and Casgevy are gaining traction, with non-CF revenue expected to exceed $500M in 2026. Inaxaplin's positive Phase 2 kidney data validated its mechanism, and ALYFTREK advanced in Canada.

    These new pipeline and commercial updates show diversification and future growth potential.

  • Competition and valuation risks persist Novartis' Fabhalta is already approved in IgA nephropathy, posing a threat to Vertex's povetacicept. Vertex trades at a premium valuation, and 2026 earnings estimates have slipped.

    This counterweight highlights ongoing risks that could pressure the stock.

Latest
▲4

Vertex's $10B Crinetics Deal, Kidney Data and ALYFTREK Win Drive Upside

  • Crinetics acquisition adds new endocrine franchise Vertex agreed to buy Crinetics for about $10 billion, adding an approved acromegaly drug and a late-stage hormone disorder treatment. The deal opens a new treatment area beyond cystic fibrosis and is expected to add to operating income by 2029, supporting a higher stock price.

    This is the period's biggest strategic move, diversifying Vertex beyond CF and adding a new growth engine.

  • CASGEVY expanded to young children; ALYFTREK advances in Canada The FDA widened CASGEVY's approval to children as young as 2, growing the number of patients who can get the one-time gene therapy. Vertex also signed a Canadian access deal for ALYFTREK, its next-generation CF drug, moving it toward public reimbursement for about 3,800 patients.

    These regulatory and access wins broaden the patient base for two key products, lifting future sales potential.

  • ALYFTREK restores pancreatic function in young CF children New interim data showed ALYFTREK restored pancreatic function in some children ages 2 to 5 with cystic fibrosis, letting many stop enzyme replacement therapy. This suggests treating CF earlier can reverse damage once thought permanent, strengthening ALYFTREK's long-term role and pricing power.

    This clinical win reinforces Vertex's core CF franchise and could expand ALYFTREK's use and pricing.

  • Kidney drug data validates APOL1 mechanism, but competition looms Positive Phase 2 data for inaxaplin in a kidney disease validated the approach and pointed to a market of over 100,000 patients. However, rivals like Novartis' Fabhalta are already approved, so Vertex must execute well to capture share and justify its pipeline value.

    This confirms a new kidney franchise but also flags real competition that could cap upside.

September 2026
▲3

Vertex's $10B Crinetics Buy and Kidney Pipeline Progress Drive Upside

  • Crinetics acquisition diversifies beyond CF Vertex completed its $10 billion purchase of Crinetics, adding Palsonify (approved for acromegaly) and atumelnant (late-stage for a hormone disorder). This opens a new treatment area beyond cystic fibrosis, supporting long-term growth and a higher stock price.

    This is the period's biggest new event, directly expanding Vertex's business and analyst price targets.

  • Morgan Stanley starts with Overweight and $665 target Morgan Stanley resumed coverage with an Overweight rating and a $665 price target, citing the Crinetics deal's diversification. The analyst raised Vertex's long-term revenue growth estimate to 13.8% from 12.1%, which helps justify a higher valuation.

    A major analyst upgrade directly influences investor sentiment and price targets.

  • Positive kidney drug data and FDA filing progress Vertex reported positive Phase IIb data for inaxaplin in a kidney disease, showing large reductions in protein in urine, and completed enrollment in a pivotal study. The FDA also accepted its filing for povetacicept, with a decision due Nov. 30, 2026. These advance a new kidney franchise.

    New clinical and regulatory progress adds a potential multi-billion-dollar revenue stream beyond CF.

  • Competition in kidney disease and high deal premium Vertex's kidney pipeline faces competition: Novartis' Fabhalta and other drugs are already approved for IgA nephropathy. Also, Vertex paid a roughly 100% premium for Crinetics, raising the bar for success. These factors could limit upside if execution disappoints.

    Provides a fair counterweight to the positive news, highlighting real risks.

▲3

Vertex's $10B Crinetics Buy and Kidney Pipeline Progress Drive Upside

  • Crinetics acquisition diversifies beyond CF Vertex completed its $10 billion purchase of Crinetics, adding Palsonify (approved for acromegaly) and atumelnant (late-stage for a hormone disorder). This opens a new treatment area beyond cystic fibrosis, supporting long-term growth and a higher stock price.

    This is the period's biggest new event, directly expanding Vertex's business and analyst price targets.

  • Morgan Stanley starts with Overweight and $665 target Morgan Stanley resumed coverage with an Overweight rating and a $665 price target, citing the Crinetics deal's diversification. The analyst raised Vertex's long-term revenue growth estimate to 13.8% from 12.1%, which helps justify a higher valuation.

    A major analyst upgrade directly influences investor sentiment and price targets.

  • Positive kidney drug data and FDA filing progress Vertex reported positive Phase IIb data for inaxaplin in a kidney disease, showing large reductions in protein in urine, and completed enrollment in a pivotal study. The FDA also accepted its filing for povetacicept, with a decision due Nov. 30, 2026. These advance a new kidney franchise.

    New clinical and regulatory progress adds a potential multi-billion-dollar revenue stream beyond CF.

  • Competition in kidney disease and high deal premium Vertex's kidney pipeline faces competition: Novartis' Fabhalta and other drugs are already approved for IgA nephropathy. Also, Vertex paid a roughly 100% premium for Crinetics, raising the bar for success. These factors could limit upside if execution disappoints.

    Provides a fair counterweight to the positive news, highlighting real risks.

▲3

Vertex Rises as Rival CF Drug Fails and Guidance Climbs

  • Rival CF drug failure clears competitive threat Sionna's SION-719 failed its Phase 2a trial, and the company dropped the program. That removes a would-be competitor to Vertex's cystic fibrosis franchise, which brings in most of its revenue. Less competition means Vertex can keep its dominant share and pricing power, pushing the stock up.

    This is the biggest new event of the period and directly lifts Vertex's core CF business.

  • Q2 revenue beat and raised 2026 guidance Vertex reported Q2 revenue of $3.33 billion, up 12.5% and above estimates, and raised full-year revenue guidance to $13.1–$13.2 billion. It also completed a $1.42 billion share buyback. Strong sales and a brighter outlook support a higher stock price.

    The quarter's results and guidance are the core financial driver behind the stock's move.

  • Non-CF products gaining traction Newer non-CF drugs Journavx and Casgevy posted combined Q2 sales of $126 million, and Vertex expects non-CF revenue to top $500 million in 2026, up about 185%. This shows the company is building growth beyond cystic fibrosis, which supports a higher valuation.

    It shows the post-CF growth story is real, a key reason investors are paying up for the stock.

  • Kidney competition and valuation keep a lid on gains Novartis' Fabhalta is already fully approved for IgA nephropathy, while Vertex's povetacicept faces an FDA decision by Nov. 30, 2026. Vertex also trades at a premium to peers, and 2026 earnings estimates have slipped. These are real counterweights that could limit upside.

    It gives the fair counterweight: competition and a rich valuation could cap further gains.

July 2026
▲3▼1

Vertex's Q2 beat and Crinetics deal drive growth, but kidney competition looms

  • Q2 revenue surges 12% to $3.3B, guidance raised Vertex reported Q2 revenue of $3.3 billion, up 12% year-over-year, driven by CF and newer products. Full-year guidance was raised to $13.1–13.2 billion, and EPS beat expectations. This strong financial performance supports a higher stock price by showing robust demand and execution.

    This is the most recent and direct positive financial update, showing accelerating growth and raised outlook.

  • Crinetics acquisition adds $5B peak sales potential Vertex agreed to acquire Crinetics for $10 billion, gaining paltusotine (PALSONIFY) and atumelnant. The deal is expected to add up to $5 billion in peak revenue and diversify beyond CF. While it uses cash, the strategic fit and growth potential outweigh the cost.

    This is a major strategic move that expands Vertex's rare disease portfolio and long-term growth prospects.

  • Novartis' Fabhalta full approval intensifies kidney competition The FDA granted full approval to Novartis' Fabhalta for IgA nephropathy, a direct competitor to Vertex's povetacicept (target action date Nov 30, 2026). This could limit povetacicept's market share and pricing power, posing a risk to Vertex's kidney pipeline.

    This is a new competitive threat that could impact a key growth driver for Vertex.

  • Casgevy approval expanded to children as young as 2 The FDA expanded Casgevy's approval to treat children aged 2 and older with sickle cell disease or thalassemia. This broadens the eligible patient population and strengthens Vertex's gene therapy franchise, though real-world uptake and reimbursement will determine the actual revenue impact.

    This regulatory win opens a new pediatric market for Casgevy, supporting long-term growth.

▲3▼1

Vertex's Q2 beat and Crinetics deal drive growth, but kidney competition looms

  • Q2 revenue surges 12% to $3.3B, guidance raised Vertex reported Q2 revenue of $3.3 billion, up 12% year-over-year, driven by CF and newer products. Full-year guidance was raised to $13.1–13.2 billion, and EPS beat expectations. This strong financial performance supports a higher stock price by showing robust demand and execution.

    This is the most recent and direct positive financial update, showing accelerating growth and raised outlook.

  • Crinetics acquisition adds $5B peak sales potential Vertex agreed to acquire Crinetics for $10 billion, gaining paltusotine (PALSONIFY) and atumelnant. The deal is expected to add up to $5 billion in peak revenue and diversify beyond CF. While it uses cash, the strategic fit and growth potential outweigh the cost.

    This is a major strategic move that expands Vertex's rare disease portfolio and long-term growth prospects.

  • Novartis' Fabhalta full approval intensifies kidney competition The FDA granted full approval to Novartis' Fabhalta for IgA nephropathy, a direct competitor to Vertex's povetacicept (target action date Nov 30, 2026). This could limit povetacicept's market share and pricing power, posing a risk to Vertex's kidney pipeline.

    This is a new competitive threat that could impact a key growth driver for Vertex.

  • Casgevy approval expanded to children as young as 2 The FDA expanded Casgevy's approval to treat children aged 2 and older with sickle cell disease or thalassemia. This broadens the eligible patient population and strengthens Vertex's gene therapy franchise, though real-world uptake and reimbursement will determine the actual revenue impact.

    This regulatory win opens a new pediatric market for Casgevy, supporting long-term growth.

Q2 2026
▲4

Vertex expands kidney, gene therapy, and rare disease reach

  • Kidney pipeline could add billions Vertex's kidney disease pipeline, including povetacicept and inaxaplin, is seen as a multi-billion-dollar growth driver. Positive late-stage data and a rolling FDA submission for povetacicept could diversify revenue beyond cystic fibrosis, lifting long-term sales expectations.

    This is a new growth opportunity that expands Vertex's revenue base and supports a higher valuation.

  • Casgevy approved for young children The FDA approved Casgevy for children as young as 2, expanding the market by about 5,500 U.S. patients and a $12.1 billion commercial opportunity. This regulatory win boosts Vertex's gene therapy revenue potential and strengthens its diversification story.

    A major regulatory expansion directly increases the addressable market and future sales for a key Vertex product.

  • Vertex to buy Crinetics for $10 billion Vertex agreed to acquire Crinetics Pharmaceuticals for about $10 billion, adding the acromegaly drug paltusotine and other assets. The deal is expected to immediately boost revenue and contribute to operating profit by 2029, with over $5 billion in peak annual revenue potential.

    This large acquisition expands Vertex's rare disease portfolio and provides near-term revenue growth, a key driver of the stock.

  • ALYFTREK gains Canadian reimbursement Vertex signed a Letter of Intent with the pan-Canadian Pharmaceutical Alliance for ALYFTREK, making about 3,800 cystic fibrosis patients in Canada eligible. This expands access to Vertex's newest CF therapy, supporting incremental revenue growth in a core franchise.

    New reimbursement expands the market for a key cystic fibrosis product, directly supporting Vertex's revenue.

June 2026
▲4

Vertex expands kidney, gene therapy, and rare disease reach

  • Kidney pipeline could add billions Vertex's kidney disease pipeline, including povetacicept and inaxaplin, is seen as a multi-billion-dollar growth driver. Positive late-stage data and a rolling FDA submission for povetacicept could diversify revenue beyond cystic fibrosis, lifting long-term sales expectations.

    This is a new growth opportunity that expands Vertex's revenue base and supports a higher valuation.

  • Casgevy approved for young children The FDA approved Casgevy for children as young as 2, expanding the market by about 5,500 U.S. patients and a $12.1 billion commercial opportunity. This regulatory win boosts Vertex's gene therapy revenue potential and strengthens its diversification story.

    A major regulatory expansion directly increases the addressable market and future sales for a key Vertex product.

  • Vertex to buy Crinetics for $10 billion Vertex agreed to acquire Crinetics Pharmaceuticals for about $10 billion, adding the acromegaly drug paltusotine and other assets. The deal is expected to immediately boost revenue and contribute to operating profit by 2029, with over $5 billion in peak annual revenue potential.

    This large acquisition expands Vertex's rare disease portfolio and provides near-term revenue growth, a key driver of the stock.

  • ALYFTREK gains Canadian reimbursement Vertex signed a Letter of Intent with the pan-Canadian Pharmaceutical Alliance for ALYFTREK, making about 3,800 cystic fibrosis patients in Canada eligible. This expands access to Vertex's newest CF therapy, supporting incremental revenue growth in a core franchise.

    New reimbursement expands the market for a key cystic fibrosis product, directly supporting Vertex's revenue.

▲4

Vertex expands kidney, gene therapy, and rare disease reach

  • Kidney pipeline could add billions Vertex's kidney disease pipeline, including povetacicept and inaxaplin, is seen as a multi-billion-dollar growth driver. Positive late-stage data and a rolling FDA submission for povetacicept could diversify revenue beyond cystic fibrosis, lifting long-term sales expectations.

    This is a new growth opportunity that expands Vertex's revenue base and supports a higher valuation.

  • Casgevy approved for young children The FDA approved Casgevy for children as young as 2, expanding the market by about 5,500 U.S. patients and a $12.1 billion commercial opportunity. This regulatory win boosts Vertex's gene therapy revenue potential and strengthens its diversification story.

    A major regulatory expansion directly increases the addressable market and future sales for a key Vertex product.

  • Vertex to buy Crinetics for $10 billion Vertex agreed to acquire Crinetics Pharmaceuticals for about $10 billion, adding the acromegaly drug paltusotine and other assets. The deal is expected to immediately boost revenue and contribute to operating profit by 2029, with over $5 billion in peak annual revenue potential.

    This large acquisition expands Vertex's rare disease portfolio and provides near-term revenue growth, a key driver of the stock.

  • ALYFTREK gains Canadian reimbursement Vertex signed a Letter of Intent with the pan-Canadian Pharmaceutical Alliance for ALYFTREK, making about 3,800 cystic fibrosis patients in Canada eligible. This expands access to Vertex's newest CF therapy, supporting incremental revenue growth in a core franchise.

    New reimbursement expands the market for a key cystic fibrosis product, directly supporting Vertex's revenue.